Merck’s Vytorin Litigation Saga Ends With $688 Million Securities Class Action Settlements

Investors alleged they lost money from the nearly two-year delay in release of results of the Enhance trial; Merck and Schering previously paid $5.4 million to states to resolve Enhance investigation.